Geron Corporation's stock dropped 50% before its Q4 2024 earnings report, with Rytelo's revenue close to projections but new ...

Geron (NASDAQ:GERN) stock plunged 30% after management reportedly indicated on the company's Q4 earnings call that sales of ...

Geron Corp (GERN) reports a robust cash reserve and key FDA approval for Rytelo, but faces flat revenue trends and leadership changes in its commercial strategy.

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Hello and welcome to the Geron fourth quarter and full year 2024 earnings call. All lines have been placed on mute to prevent any background noise. Aft ...

Geron ended 2024 with a strong cash position and reported that revenues for the third and fourth quarters exceeded expectations. The company’s net product revenue for RYTELO reached $47.5 million in ...

Scotiabank lowered the firm’s price target on Geron (GERN) to $4 from $6 and keeps an Outperform rating on the shares. While the company’s Q4 ...

Geron shares fell 30% to $1.66 after the company reported a fourth-quarter loss that was wider than expected.

Geron's first-in-class cancer drug Rytelo, recently approved by the FDA for myelodysplastic syndromes (MDS), is priced three to four times higher than it should be, according to the Institute for ...

We recently published a list of 10 Best Nasdaq Stocks Under $5 to Buy. In this article, we are going to take a look at where ...